{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T03:07:51Z","timestamp":1789182471794,"version":"build-2803163510"},"reference-count":33,"publisher":"Wiley","license":[{"start":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T00:00:00Z","timestamp":1789084800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T00:00:00Z","timestamp":1789084800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["UMEA FU 356\/12\u20102"],"award-info":[{"award-number":["UMEA FU 356\/12\u20102"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005972","name":"Deutsche Krebshilfe","doi-asserted-by":"publisher","award":["1117240"],"award-info":[{"award-number":["1117240"]}],"id":[{"id":"10.13039\/501100005972","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005972","name":"Deutsche Krebshilfe","doi-asserted-by":"publisher","award":["70113041"],"award-info":[{"award-number":["70113041"]}],"id":[{"id":"10.13039\/501100005972","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["European J of Haematology"],"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>Primary plasma cell leukemia (pPCL) is a rare disease with poor outcomes. As data on randomized phase\u2010III trials are lacking, treatment recommendations are predominately based on retrospective analyses incorporating time periods with outdated therapies. Thus, the optimal consolidation strategy remains to be defined.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a retrospective, multi\u2010center analysis with 49 transplant\u2010eligible patients diagnosed with pPCL between 2011 and 2025 focusing on different stem cell transplantation (SCT) strategies as consolidation treatment in first remission: single autologous (auto) or single allogeneic (allo) SCT versus patients with tandem cell therapy strategies (auto\u2010auto, allo\u2010auto, auto\u2010chimeric antigen receptor therapy).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The median follow\u2010up after first SCT was 31\u2009months. The cumulative incidence of initiating next treatment was lower after tandem cell therapy compared to single SCT (at 12\u2009months: 42% vs. 57%,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.006). Moreover, in a multivariable analysis incorporating cytogenetic risk and response to induction therapy, tandem transplantation strategies tended to be the only independent predictor for prolonged time to next treatment (TTNT,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.077). Noteworthy, differences in TTNT between patients with a single SCT and patients with tandem cell therapy did not translate into an improved overall survival, possibly due to potent salvage therapies.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Our data support recent recommendations advising treating patients with tandem transplantation regimes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/ejh.70319","type":"journal-article","created":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T03:02:18Z","timestamp":1789182138000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Transplantation Strategies in Treatment of Primary Plasma Cell Leukemia in Germany\u2014A Multi\u2010Center Analysis"],"prefix":"10.1111","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1418-3269","authenticated-orcid":false,"given":"Maria","family":"Dampmann","sequence":"first","affiliation":[{"name":"Department of Hematology and Stem Cell Transplantation, West German Cancer Center University Hospital Essen, University Duisburg\u2010Essen  Essen Germany"},{"name":"Department of Medical Oncology University Hospital Essen, West German Cancer Center  Essen Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0642-7104","authenticated-orcid":false,"given":"Sarah","family":"Flossdorf","sequence":"additional","affiliation":[{"name":"Institute for Medical Informatics, Biometry and Epidemiology University Hospital Essen  Essen Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5617-091X","authenticated-orcid":false,"given":"Julius","family":"Keyl","sequence":"additional","affiliation":[{"name":"Institute for Artificial Intelligence in Medicine University Hospital Essen  Essen Germany"},{"name":"Institute of Pathology, University Hospital Essen  Essen Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theo","family":"Leitner","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, University of Luebeck University Cancer Center Schleswig\u2010Holstein (UCCSH) and University Hospital Schleswig\u2010Holstein (UKSH), Campus Luebeck  Luebeck Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cyrus","family":"Khandanpour","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, University of Luebeck University Cancer Center Schleswig\u2010Holstein (UCCSH) and University Hospital Schleswig\u2010Holstein (UKSH), Campus Luebeck  Luebeck Germany"},{"name":"Department of Hematology and Oncology, Carl\u2010von\u2010Ossietzky University Oldenburg Klinikum Oldenburg and University Cancer Center Northwest  Oldenburg Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-7585-8956","authenticated-orcid":false,"given":"Markus","family":"Maulhardt","sequence":"additional","affiliation":[{"name":"Department of Hematology and Medical Oncology University Medical Center G\u00f6ttingen  G\u00f6ttingen Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0178-1729","authenticated-orcid":false,"given":"Evgenii","family":"Shumilov","sequence":"additional","affiliation":[{"name":"Department of Medicine A, Hematology and Oncology University Hospital of M\u00fcnster  M\u00fcnster Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9331-5145","authenticated-orcid":false,"given":"Matthias","family":"Stelljes","sequence":"additional","affiliation":[{"name":"Department of Medicine A, Hematology and Oncology University Hospital of M\u00fcnster  M\u00fcnster Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9248-588X","authenticated-orcid":false,"given":"Lisa","family":"Leypoldt","sequence":"additional","affiliation":[{"name":"Department of Hematology, Oncology and Bone Marrow Transplantation With Section of Pneumology University Medical Center Hamburg\u2010Eppendorf  Hamburg Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-0763-3823","authenticated-orcid":false,"given":"Marie","family":"Harzer","sequence":"additional","affiliation":[{"name":"Department of Hematology, Oncology and Bone Marrow Transplantation With Section of Pneumology University Medical Center Hamburg\u2010Eppendorf  Hamburg Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6494-5105","authenticated-orcid":false,"given":"Christoph","family":"Schaefers","sequence":"additional","affiliation":[{"name":"Department of Hematology, Oncology and Bone Marrow Transplantation With Section of Pneumology University Medical Center Hamburg\u2010Eppendorf  Hamburg Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francis Ayuketang","family":"Ayuk","sequence":"additional","affiliation":[{"name":"Department of Stem Cell Transplantation University Medical Center Hamburg\u2010Eppendorf  Hamburg Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1410-4487","authenticated-orcid":false,"given":"Bastian","family":"von Tresckow","sequence":"additional","affiliation":[{"name":"Department of Hematology and Stem Cell Transplantation, West German Cancer Center University Hospital Essen, University Duisburg\u2010Essen  Essen Germany"},{"name":"National Center for Tumor Diseases (NCT\u2010West) Campus University Hospital Essen  Essen Germany"},{"name":"German Cancer Consortium DKTK, Partner Site Essen  Essen Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8845-3052","authenticated-orcid":false,"given":"Amelie","family":"Boquoi","sequence":"additional","affiliation":[{"name":"Department of Hematology and Stem Cell Transplantation, West German Cancer Center University Hospital Essen, University Duisburg\u2010Essen  Essen Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Schroeder","sequence":"additional","affiliation":[{"name":"Department of Hematology and Stem Cell Transplantation, West German Cancer Center University Hospital Essen, University Duisburg\u2010Essen  Essen Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5706-9349","authenticated-orcid":false,"given":"Hans Christian","family":"Reinhardt","sequence":"additional","affiliation":[{"name":"Department of Hematology and Stem Cell Transplantation, West German Cancer Center University Hospital Essen, University Duisburg\u2010Essen  Essen Germany"},{"name":"National Center for Tumor Diseases (NCT\u2010West) Campus University Hospital Essen  Essen Germany"},{"name":"German Cancer Consortium DKTK, Partner Site Essen  Essen Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2766-1696","authenticated-orcid":false,"given":"Christine","family":"Hanoun","sequence":"additional","affiliation":[{"name":"Department of Hematology and Stem Cell Transplantation, West German Cancer Center University Hospital Essen, University Duisburg\u2010Essen  Essen Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,9,11]]},"reference":[{"issue":"12","key":"e_1_2_13_2_1","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1038\/s41408-021-00587-0","article-title":"Primary Plasma Cell Leukemia: Consensus Definition by the International Myeloma Working Group According to Peripheral Blood Plasma Cell Percentage","volume":"11","author":"Fernandez de Larrea C.","year":"2021","journal-title":"Blood Cancer Journal"},{"issue":"6","key":"e_1_2_13_3_1","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1016\/S0889-8588(05)70125-8","article-title":"Nonsecretory Myeloma, Immunoglobulin D Myeloma, and Plasma Cell Leukemia","volume":"13","author":"Blade J.","year":"1999","journal-title":"Hematology\/Oncology Clinics of North America"},{"issue":"5","key":"e_1_2_13_4_1","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1001\/archinte.133.5.813","article-title":"Plasma Cell Leukemia. Report on 17 Cases","volume":"133","author":"Kyle R. A.","year":"1974","journal-title":"Archives of Internal Medicine"},{"issue":"4","key":"e_1_2_13_5_1","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1038\/leu.2012.336","article-title":"Plasma Cell Leukemia: Consensus Statement on Diagnostic Requirements, Response Criteria and Treatment Recommendations by the International Myeloma Working Group","volume":"27","author":"Fernandez de Larrea C.","year":"2013","journal-title":"Leukemia"},{"issue":"4","key":"e_1_2_13_6_1","doi-asserted-by":"crossref","first-page":"941","DOI":"10.3324\/haematol.2022.281432","article-title":"Plasma Cell Leukemia: Another Piece of the Puzzle","volume":"108","author":"Musto P.","year":"2023","journal-title":"Haematologica"},{"issue":"4","key":"e_1_2_13_7_1","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.annonc.2025.01.022","article-title":"European Myeloma Network Group Review and Consensus Statement on Primary Plasma Cell Leukemia","volume":"36","author":"Musto P.","year":"2025","journal-title":"Annals of Oncology"},{"issue":"1","key":"e_1_2_13_8_1","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1038\/leu.2013.241","article-title":"Lenalidomide and Low\u2010Dose Dexamethasone for Newly Diagnosed Primary Plasma Cell Leukemia","volume":"28","author":"Musto P.","year":"2014","journal-title":"Leukemia"},{"issue":"18","key":"e_1_2_13_9_1","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1200\/JCO.2015.63.1929","article-title":"Bortezomib, Doxorubicin, Cyclophosphamide, Dexamethasone Induction Followed by Stem Cell Transplantation for Primary Plasma Cell Leukemia: A Prospective Phase II Study of the Intergroupe Francophone du Myelome","volume":"34","author":"Royer B.","year":"2016","journal-title":"Journal of Clinical Oncology"},{"issue":"10","key":"e_1_2_13_10_1","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1016\/S1470-2045(23)00405-9","article-title":"Treatment of Primary Plasma Cell Leukaemia With Carfilzomib and Lenalidomide\u2010Based Therapy (EMN12\/HOVON\u2010129): Final Analysis of a Non\u2010Randomised, Multicentre, Phase 2 Study","volume":"24","author":"Donk N. W. C. J.","year":"2023","journal-title":"Lancet Oncology"},{"issue":"3","key":"e_1_2_13_11_1","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1002\/cncr.31718","article-title":"Survival Outcomes of Patients With Primary Plasma Cell Leukemia (pPCL) Treated With Novel Agents","volume":"125","author":"Mina R.","year":"2019","journal-title":"Cancer"},{"issue":"6","key":"e_1_2_13_12_1","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1093\/annonc\/mdr480","article-title":"Frontline Chemotherapy With Bortezomib\u2010Containing Combinations Improves Response Rate and Survival in Primary Plasma Cell Leukemia: A Retrospective Study From GIMEMA Multiple Myeloma Working Party","volume":"23","author":"D'Arena G.","year":"2012","journal-title":"Annals of Oncology"},{"issue":"5","key":"e_1_2_13_13_1","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1002\/ajh.26891","article-title":"Improved Survival of Patients With Primary Plasma Cell Leukemia With VRd or Daratumumab\u2010Based Quadruplets: A Multicenter Study by the Greek Myeloma Study Group","volume":"98","author":"Katodritou E.","year":"2023","journal-title":"American Journal of Hematology"},{"issue":"12","key":"e_1_2_13_14_1","doi-asserted-by":"crossref","first-page":"1031.e1","DOI":"10.1016\/j.jtct.2025.08.026","article-title":"Comparison of Autologous and Allogeneic Hematopoietic Stem Cell Transplantation for Primary Plasma Cell Leukemia in Japan","volume":"31","author":"Maegaki M.","year":"2025","journal-title":"Transplantation and Cellular Therapy"},{"key":"e_1_2_13_15_1","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.3324\/haematol.2021.280568","article-title":"Comparison of Autologous and Allogeneic Hematopoietic Cell Transplantation Strategies in Patients With Primary Plasma Cell Leukemia, With Dynamic Prediction Modelling","volume":"108","author":"Lawless S.","year":"2022","journal-title":"Haematologica"},{"issue":"1","key":"e_1_2_13_16_1","doi-asserted-by":"crossref","DOI":"10.1080\/16078454.2024.2343164","article-title":"Tandem Autologous Hematopoietic Stem Cell Transplantation for Patients With Multiple Myeloma: A Systematic Review and Meta\u2010Analysis","volume":"29","author":"Li H.","year":"2024","journal-title":"Hematology"},{"issue":"8","key":"e_1_2_13_17_1","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1056\/NEJMoa2024850","article-title":"Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma","volume":"384","author":"Munshi N. C.","year":"2021","journal-title":"New England Journal of Medicine"},{"issue":"2","key":"e_1_2_13_18_1","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/S1470-2045(25)00653-9","article-title":"Cilta\u2010Cel in Lenalidomide\u2010Refractory Multiple Myeloma (CARTITUDE\u20104): An Updated Analysis Including Overall Survival From an Open\u2010Label, Multicentre, Randomised, Phase 3 Trial","volume":"27","author":"Einsele H.","year":"2026","journal-title":"Lancet Oncology"},{"issue":"23","key":"e_1_2_13_19_1","doi-asserted-by":"crossref","first-page":"6009","DOI":"10.1182\/bloodadvances.2025016966","article-title":"Safety and Efficacy of BCMA\u2010Directed Chimeric Antigen Receptor T\u2010Cell Therapy for the Treatment of Plasma Cell Leukemia","volume":"9","author":"Galarza Fortuna G. M.","year":"2025","journal-title":"Blood Advances"},{"key":"e_1_2_13_20_1","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2026.1756209","article-title":"Efficacy of BCMA CAR\u2010T Cell Therapy and Subsequent Strategies in Refractory and Relapsed Plasma Cell Leukemia: A Retrospective Cohort Study","volume":"17","author":"Guo Y.","year":"2026","journal-title":"Frontiers in Immunology"},{"issue":"5","key":"e_1_2_13_21_1","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1038\/leu.2011.312","article-title":"Hematopoietic Cell Transplantation for Primary Plasma Cell Leukemia: Results From the Center for International Blood and Marrow Transplant Research","volume":"26","author":"Mahindra A.","year":"2012","journal-title":"Leukemia"},{"issue":"12","key":"e_1_2_13_22_1","doi-asserted-by":"crossref","first-page":"3338","DOI":"10.1038\/s41375-020-0830-0","article-title":"Hematopoietic Cell Transplantation Utilization and Outcomes for Primary Plasma Cell Leukemia in the Current Era","volume":"34","author":"Dhakal B.","year":"2020","journal-title":"Leukemia"},{"key":"e_1_2_13_23_1","doi-asserted-by":"crossref","DOI":"10.1016\/j.leukres.2024.107640","article-title":"Outcomes of Hematopoietic Stem Cell Transplantation in Primary Plasma Cell Leukemia: A Systematic Review and Meta\u2010Analysis","volume":"148","author":"Shahzad M.","year":"2025","journal-title":"Leukemia Research"},{"issue":"1","key":"e_1_2_13_24_1","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1200\/JCO.23.01696","article-title":"Isatuximab, Carfilzomib, Lenalidomide, and Dexamethasone for the Treatment of High\u2010Risk Newly Diagnosed Multiple Myeloma","volume":"42","author":"Leypoldt L. B.","year":"2024","journal-title":"Journal of Clinical Oncology"},{"issue":"23","key":"e_1_2_13_25_1","doi-asserted-by":"crossref","first-page":"3945","DOI":"10.1200\/JCO.22.02567","article-title":"Daratumumab, Cyclophosphamide, Bortezomib, Lenalidomide, and Dexamethasone as Induction and Extended Consolidation Improves Outcome in Ultra\u2010High\u2010Risk Multiple Myeloma","volume":"41","author":"Kaiser M. F.","year":"2023","journal-title":"Journal of Clinical Oncology"},{"issue":"6","key":"e_1_2_13_26_1","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1056\/NEJMoa2203478","article-title":"Teclistamab in Relapsed or Refractory Multiple Myeloma","volume":"387","author":"Moreau P.","year":"2022","journal-title":"New England Journal of Medicine"},{"issue":"10297","key":"e_1_2_13_27_1","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/S0140-6736(21)00933-8","article-title":"Ciltacabtagene Autoleucel, a B\u2010Cell Maturation Antigen\u2010Directed Chimeric Antigen Receptor T\u2010Cell Therapy in Patients With Relapsed or Refractory Multiple Myeloma (CARTITUDE\u20101): A Phase 1b\/2 Open\u2010Label Study","volume":"398","author":"Berdeja J. G.","year":"2021","journal-title":"Lancet"},{"issue":"24","key":"e_1_2_13_28_1","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1056\/NEJMoa2204591","article-title":"Talquetamab, A T\u2010Cell\u2010Redirecting GPRC5D Bispecific Antibody for Multiple Myeloma","volume":"387","author":"Chari A.","year":"2022","journal-title":"New England Journal of Medicine"},{"issue":"9","key":"e_1_2_13_29_1","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1038\/s41591-023-02528-9","article-title":"Elranatamab in Relapsed or Refractory Multiple Myeloma: Phase 2 MagnetisMM\u20103 Trial Results","volume":"29","author":"Lesokhin A. M.","year":"2023","journal-title":"Nature Medicine"},{"key":"e_1_2_13_30_1","doi-asserted-by":"crossref","first-page":"5938","DOI":"10.1182\/bloodadvances.2026020826","article-title":"Real\u2010World Outcomes With BCMA\u2010 and GPRC5D\u2010Targeting Bispecific Antibodies in Plasma Cell Leukemia","volume":"10","author":"Gaballa M. R.","year":"2026","journal-title":"Blood Advances"},{"issue":"6","key":"e_1_2_13_31_1","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1182\/blood.2023022823","article-title":"Correlation of Immune Fitness With Response to Teclistamab in Relapsed\/Refractory Multiple Myeloma in the MajesTEC\u20101 Study","volume":"144","author":"Cortes\u2010Selva D.","year":"2024","journal-title":"Blood"},{"key":"e_1_2_13_32_1","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1495233","article-title":"Anti\u2010BCMA and GPRC5D Bispecific Antibodies in Relapsed\/Refractory Primary Plasma Cell Leukemia: A Case Report","volume":"15","author":"Bernardi C.","year":"2024","journal-title":"Frontiers in Immunology"},{"issue":"19","key":"e_1_2_13_33_1","doi-asserted-by":"crossref","first-page":"2176","DOI":"10.1182\/blood.2025032536","article-title":"Dual\u2010Antigen\u2010Targeting T\u2010Cell Immunotherapies in MM: Circumventing Tumor Heterogeneity and Preventing Antigen Escape","volume":"147","author":"Donk N.","year":"2026","journal-title":"Blood"},{"issue":"2","key":"e_1_2_13_34_1","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1056\/NEJMoa2406536","article-title":"Talquetamab Plus Teclistamab in Relapsed or Refractory Multiple Myeloma","volume":"392","author":"Cohen Y. C.","year":"2025","journal-title":"New England Journal of Medicine"}],"container-title":["European Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ejh.70319","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/ejh.70319","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ejh.70319","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T03:02:24Z","timestamp":1789182144000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ejh.70319"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,11]]},"references-count":33,"alternative-id":["10.1111\/ejh.70319"],"URL":"https:\/\/doi.org\/10.1111\/ejh.70319","archive":["Portico"],"relation":{},"ISSN":["0902-4441","1600-0609"],"issn-type":[{"value":"0902-4441","type":"print"},{"value":"1600-0609","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,11]]},"assertion":[{"value":"2026-05-19","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-09-02","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-09-11","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"ejh.70319"}}